Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
5 Results for "
ubiquitin-proteasomal pathway
" in MedChemExpress (MCE) Product Catalog:
Products (5)
5 Results for "ubiquitin-proteasomal pathway" in MCE Product Catalog:
2
2 Cited Publications
Cat. No.: HY-N10549
CAS No.: 83088-28-2
Cat. No.: HY-168274
CAS No.: 3100306-42-8
Target:
Research Areas:
PROTAC TRIB2 degrader-1 is a selective TRIB2 PROTAC degrader with a DC50 of 16.84 nM in PC3 cells. PROTAC TRIB2 degrader-1 directly interacts with TRIB2 and induces its degradation via the CRBN-dependent ubiquitin-proteasome pathway. PROTAC TRIB2 degrader-1 inhibits cancer cell proliferation and promotes apoptosis by inducing PARP cleavage. PROTAC TRIB2 degrader-1 is applicable to relevant research on prostate cancer .
Cat. No.: HY-179033
Nur77 antagonist 2 (Compound 12b) is an orally active Nur77 antagonist with a KD value of 0.42 μM. Nur77 antagonist 2 exhibits proliferative activity on liver cancer cells. Nur77 antagonist 2 stabilizes Nur77 by inhibiting its ubiquitin-proteasomal degradation,
leading to Nur77-dependent apoptosis via the ASK1-JNK/p38 pathway. Nur77 antagonist 2 inhibits tumor growth in the HCCLM3 xenograft model. Nur77 antagonist 2 can be used for the study of hepatocellular carcinoma (HCC) .
Cat. No.: HY-186247
CAS No.: 885986-52-7
Research Areas:
N-Myc-IN-1 is a selective N-Myc inhibitor/degrader with a Kd value of 1.47 μM. N-Myc-IN-1 promotes phosphorylation of N-Myc at threonine-58, triggers N-Myc degradation via the ubiquitin-proteasome pathway, and suppresses the expression of N-Myc target genes. N-Myc-IN-1 reduces the viability of MYCN-dependent tumor cells and induces apoptosis. N-Myc-IN-1 can be used in the research of neuroblastoma .
Cat. No.: HY-184335
CAS No.: 3097564-20-7
Research Areas:
PROTAC BET Degrader-18 is a PROTAC targeting BET, with a DC50 of 0.676 nM in HEK293-BRD4-HiBiT-KI cells. PROTAC BET Degrader-18 mainly targets and degrades BRD4 (EC50 = 59.91 nM), and exhibits weak degradation activity against BRD2. PROTAC BET Degrader-18 inhibits the expression of downstream oncoprotein c-Myc, thereby inducing cell cycle arrest and apoptosis, while suppressing oncoprotein expression. PROTAC BET Degrader-18 shows antiproliferative activity against acute myeloid leukemia cells and triple-negative breast cancer cells. PROTAC BET Degrader-18 demonstrates antitumor efficacy in xenograft mouse models. PROTAC BET Degrader-18 can be used for the research of acute myeloid leukemia and triple-negative breast cancer .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
